Cite
HARVARD Citation
Dittus, C. et al. (2018). Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. Leukemia & lymphoma. 59 (9), pp. 2121-2127. [Online].